CureVac NV (Nasdaq: CVAC), headquartered in Germany with a U.S. office in Boston, announced on Wednesday that its Covid-19 vaccine candidate was just 47% effective against "any severity" of the disease in an interim analysis, failing to meet the criteria the company had initially laid out.
Read More
